profit from every $100 of sales.
$0$100
Genprex
$2.08-5.88% today
-97.5% in 1 year
1-year low $1.811-year high $88.60
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Genprex sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$16.2 million of profit last year.
SalesProfit
Genprex vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Genprex | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Genprex's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -24 | -31 | -21 | -16 | |
| -24 | -31 | -21 | -15 | |
| -24 | -31 | -21 | -16 | |
| -990.00 | -22.56 | -266.89 | -17.40 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 25 | 11 | 4 | 10 |
| Cash | 21 | 7 | 2 | 8 |
| Total debt | – | – | – | – |
| Total liabilities | 3 | 3 | 3 | 2 |
| 22 | 7 | 2 | 8 | |
| 1 | 1 | 0 | 1 | |
| -84.5% | -330.8% | -1,029.4% | -153.7% | |
| -106.6% | -416.1% | -1,303.0% | -203.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -18 | -25 | -18 | -15 | |
| 0 | 0 | – | – | |
| -18 | -25 | -18 | -15 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 5 | 5 | 3 | 0 |
Valuation
- –
- –
- –
- 0.1×
- –
- –
- 0.4×
- -898.0%
- -951.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -194.3%
- -415.9%
- -464.1%
- -159.7%
- -194.3%
- –
Growth
- –
- –
- +10.7%
- –
- +150.9%
Financial health
- -0.5×
- 0.00
- 0.0%
- –
- 3.84
- 3.84
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 884
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.64 | – | – |
| Mar 30, 2026 | -1.15 | -13.00 | +91.2% |
| Nov 14, 2025 | -5.00 | -12.50 | +60.0% |
| Aug 14, 2025 | -8.50 | -21.00 | +59.5% |
| May 12, 2025 | -0.26 | -0.82 | +68.3% |
| Apr 7, 2025 | -1.15 | -0.82 | −40.2% |
| Nov 13, 2024 | -1.23 | -1.13 | −8.8% |
| Aug 9, 2024 | -3.00 | -2.30 | −30.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
79Pass
Philip Fisher
42No pass
Peter Lynch
60Pass
Joel Greenblatt
50No pass
Charlie Munger
38No pass
Terry Smith
34No pass
Questions about Genprex
Is Genprex a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Genprex AI analysis
What does Genprex do?
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. It is in Biotechnology.
Does Genprex pay a dividend?
No. Genprex does not pay a dividend at the moment.
Is Genprex stock halal?
No. Genprex does not pass our halal screen: its cash and confirmed interest-bearing investments are 459% of its market value, at or above the 33% limit. How we check
How has Genprex stock done over the past year?
Down 97.5% over the past twelve months, to $2.08. It traded between $1.81 and $88.60 and is 97.7% below its high.
Who are Genprex's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Genprex's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.